Taurine Supplementation Inhibits the Expression of Atrogin-1 and MURF-1, Protein Degradation Marker Genes, in Skeletal Muscle of C26-Induced Cachexia Mouse Model

Adv Exp Med Biol. 2022:1370:129-136. doi: 10.1007/978-3-030-93337-1_12.

Abstract

This study was designed to investigate the therapeutic effects of taurine in attenuating muscle atrophy. C26 carcinoma cells were cultured and injected into the scapulae of Balb/c mice with 1 × 106 cells. Taurine (200 μl suspension) was orally administered at the concentration of 200 mg/kg of body weight for 2 weeks. Femur muscle tissue, spleen, and gonadal fat tissue were collected and weighed. Muscle tissue was stained by H&E for histopathological analysis. The transcriptional expression of atrogin-1 and MuRF-1 gene was checked by real-time PCR. C26 cells, which induced tumor growth, caused a loss in muscle mass and gonadal fat tissue mass. Simultaneously, there was an increase in spleen and tumor tissue mass. In contrast, taurine supplementation showed a downregulatory effect on the transcriptional expression profile of muscle degradative factors atrogin-1 and MuRF-1. Our findings suggest that taurine has the potential to inhibit muscle atrophy and can be developed as a safe treatment option against muscle loss in sarcopenia patients.

Keywords: Atrogin-1; MuRF-1; Sarcopenia; Skeletal muscle.

MeSH terms

  • Animals
  • Cachexia* / drug therapy
  • Cachexia* / genetics
  • Dietary Supplements
  • Disease Models, Animal
  • Mice
  • Muscle, Skeletal / metabolism
  • Muscular Atrophy / drug therapy
  • Muscular Atrophy / genetics
  • Neoplasms* / pathology
  • Proteolysis
  • Taurine / metabolism
  • Taurine / pharmacology
  • Taurine / therapeutic use

Substances

  • Taurine